SCHEMBL13020480

SCHEMBL13020480

COC1C(CO)OC(n2cnc3c(N)ncnc32)C1OP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)C(OP(=O)(S)OCC2OC(n3cnc4c(N)ncnc43)C(O)C2O)C1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 4/20 0.67
▸ P2RY2 P41231 3/20 0.67
▸ SRC P12931 2/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ TRPM2 O94759 2/20 0.67
▸ ADORA1 P30542 2/20 0.67
▸ DNPH1 O43598 1/20 0.67
▸ PRKAB2 O43741 1/20 0.67
▸ LDHA P00338 1/20 0.67
▸ ADRB2 P07550 1/20 0.67
▸ FBP1 P09467 1/20 0.67
▸ PRKAG1 P54619 1/20 0.67
▸ PRKAA2 P54646 1/20 0.67
▸ PDE4D Q08499 1/20 0.67
▸ KCNH2 Q12809 1/20 0.67
▸ PRKAA1 Q13131 1/20 0.67
▸ PDE3A Q14432 1/20 0.67
▸ TAS1R3 Q7RTX0 1/20 0.67
▸ TAS1R1 Q7RTX1 1/20 0.67
▸ P2RY11 Q96G91 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020730 1.00 P2RY1 (0.67) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL12963654 0.98 RNASEL (0.69) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL12963356 0.93 P2RY1 (0.60) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL13020747 0.93 P2RY1 (0.66) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL13020505 0.93 P2RY1 (0.66) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL23624817 0.92 ADORA1 (0.64) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL13020481 0.92 P2RY1 (0.58) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL13020738 0.91 RNASEL (0.79) P2RY1RNASEL
SCHEMBL13020500 0.91 RNASEL (0.79) P2RY1RNASEL
SCHEMBL13020487 0.91 RNASEL (0.73) P2RY1P2RY2SRCSMN1; SMN2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2010-12-30 — — US disclosed
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE RNASEL, RNASE1, RNASEH1 P2RY1 3036/4885P2RY2 2712/4885SRC 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback